Targeting Obesity and MASH with a Pipeline
of Next Generation Therapeutics

MetaVia is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH).

OUR PROGRAMS

DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), in development for the treatment of obesity. DA-1241 is a novel, G-Protein-Coupled Receptor 119 (GPR119) agonist in development for the treatment of MASH.